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Diabetic macular edema (DME) is a major cause of visual impairment in diabetic patients. Laser
photocoagulation is the standard management strategy for macular edema, but its results remain
unsatisfactory. Several clinical trials of new treatment modalities for DME have been conducted over the
past 10 years. We performed a literature search of English articles, published between 2000 and 2010, by
using the PubMed database. The keywords searched included “diabetic macular edema and treatment”
with limits set to include only clinical trials and review articles, over 50 articles were reviewed. Among
the newer treatment modalities reviewed, therapy with anti-vascular endothelial growth factor (VEGF)
antibodies showed signiﬁcantly better efﬁcacy, with level I evidence. However, multiple injections were
required to maintain its efﬁcacy. Therefore, the associated complications and cost implications are the
major limitations of this treatment. Several combinations of different modalities have been evaluated in
the literature, but none are more efﬁcacious than monotherapy with anti-VEGF antibodies. Since DME is
a multifactorial disease, further studies involving combinations of modalities or new treatments
modalities may be needed to reduce the number of injections required or improve the visual outcomes in
case of DME.
Copyright  2011, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Diabetic mellitus is an important issue in public health, espe-
cially in the elderly. More than 220 million people worldwide have
diabetes (90% type 2 diabetes). Ten percent of these develop severe
visual impairment after 15 years of diabetes1. According to a study
by Chan et al2, the prevalence of type 2 diabetes in the old age
group (> 60 years old) in Taiwan was signiﬁcantly greater than in
the young age group (20w 40 years old) in both genders. The
prevalence in old age groups was 20.5w 26.3% and that in youngsts related to the material in
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iwan Society of Geriatric Emergenage groupswas 0.6w 7.6% in 2004. The elderly people have a higher
risk of severe visual impairment because of a higher prevalence and
longer duration of diabetes.
Diabetic macular edema (DME, Fig. 1) is the most common cause
of visual impairment in patients with diabetes3. The prevalence of
DME was found to be related to the duration of diabetes, as
reported in of the Wisconsin Epidemiologic Study of Diabetic
Retinopathy4. The prevalence of DME in patients with type 1 dia-
betes varied from 0% (duration of less than 5 years) to 29% (duration
of 20 years or more). The prevalence in patients with type 2 dia-
betes was similar: 3% in the group with diabetes for less than
5 years and 28% in the group with diabetes for 20 years or more.
Approximately 50% of patients with DME will experience a loss of 2
lines of best-corrected visual acuity (BCVA) after 2 years of follow-
up5. It is thus important to treat DME effectively to reduce the
possibility of visual loss. Many treatment modalities have been
reported, especially in recent years. Here, we review the clinical
trials conducted over the past 10 years for the treatment of DME
and discuss the results of the comparison studies.
2. Pathogenesis and clinical deﬁnition of DME
The pathogenesis of DME is complex and involves multiple
factors3. It occurs mainly as a result of disruption of the blood-
retinal barrier, which leads to increased accumulation of ﬂuidcy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. DME, hard exudate derived from plasma lipoproteins located within 1 disc
diameter of the center of the macula.
Fig. 2. Examples of laser photocoagulation for DME. (A) focal laser photocoagulations
(green spots) are applied on the leaking microaneurysms of focal macular edema; (B)
grid laser photocoagulations (green spots) are used to treat diffuse macular edema.
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as vascular endothelial growth factor (VEGF), protein kinase C,
histamine and others factors that are affected by hypoxia or chronic
hyperglycemia may cause breakdown of the blood-retinal barrier.
The abnormalities in the structure of the vitreoretinal interfacemay
also play an important role in the pathogenesis of DME.
The Early Treatment Diabetic Retinopathy Study (ETDRS)
deﬁned DME as retinal thickening or a presence of hard exudates
within 1 disc diameter of the center of the macula. The term
“clinically signiﬁcant macular edema” (CSME) is used to charac-
terize the severity of macular edema and for treatment guidelines.
CSME is deﬁned by the presence of one or more of the following:
retinal thickening at or within 500 mm of the center of the macula,
hard exudates at or within 500 mm of the center of the macula if
associated with adjacent retinal thickening, or a zone or zones of
retinal thickening 1 disc area in size at least part of which is within
1 disc diameter of the center of the macula6. In addition to criteria
set by the above deﬁnition, ﬂuorescein angiography and optical
coherence tomography (OCT) are useful tools to examine the
permeability of perimacular vessels and changes in retinal
thickness.
3. Current treatment modalities
3.1. Laser photocoagulation for DME
The exact mechanism of DME resolution after laser photoco-
agulation is unknown. One explanation involves laser-induced
destruction of oxygen-consuming photoreceptors. Oxygen that
normally diffuses from the choriocapillaries into the outer retina
can diffuse through the laser scar to the inner retina, thus relieving
inner retinal hypoxia. Another hypothesis explains that prolifera-
tion of the retinal pigmented epithelium (RPE) induced by laser
photocoagulation can produce cytokines to antagonize the per-
meabilizing effects of VEGF3.
Macular laser photocoagulation proposed by ETDRS (Fig. 2) is
the standard treatment for DME3. The ETDRS was a prospective,
randomized clinical trial to study the effect of laser photocoagula-
tion on DME. The result of ETDRS revealed that patients with mild
to moderate nonproliferative diabetic retinopathy (NPDR) with
DME, had signiﬁcantly lower rates of moderate visual loss (deﬁned
as a loss of 15 or more letters) in the treated group (12%) than in the
deferral group (24%) at the end of 3 years. In the treated group, the
risk of moderate visual loss reduced signiﬁcantly in the patients
with CSME, but not in the patients without CSME. The authorsrecommended that laser photocoagulation should be considered
for all eyes with CSME6.
Diffuse DME did not respond well to the grid laser treatment. At
a 3-year follow-up study of 302 eyeswith diffuse DME, Lee and Olk7
reported 15% of the eyes had visual improvement, 61% remained
unchanged, and 24% becameworse in visual acuity. Barkmeier et al8
also found the reduction of foveal thickness after laser photoco-
agulation for CSME was statistically signiﬁcant in patients with
focal parafoveal thickening, but not in patients with diffuse paraf-
oveal thickening. Complications of laser photocoagulation included
a visual decrease caused by laser-induced RPE atrophy and sub-
retinal ﬁbrosis involving the central fovea9,10.
3.2. Corticosteroids
As described by the above studies, there were many patients
with diffuse DME whose condition worsened after grid treatment.
Thus, many other modalities of DME treatment were studied.
Corticosteroids can suppress activation of the VEGF gene and
downregulate the induction of VEGF3. Peribulbar injection
(including posterior subtenon injection) alone is not an effective
treatment for DME11,12. However, posterior subtenon triamcino-
lone, as an adjunctive treatment for diffuse DME, can improve the
visual outcomes of laser photocoagulation13e15.
Intravitreal injection of triamcinolone acetonide (IVTA) as the
primary treatment of DME has been studied by the Diabetic Reti-
nopathy Clinical Research Network16. Eight hundred and forty eyes
with CSME were randomly assigned into three groups: focal/grid
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acuity was better in both IVTA groups than in the laser group in the
ﬁrst year. However, after 2 years of treatment, it signiﬁcantly better
in the laser group than in the IVTA groups. There was no signiﬁcant
difference in visual outcome between the two IVTA groups. The
main complications of IVTA were glaucoma and cataract formation
(Table 1).
Although IVTA is less effective than laser photocoagulation for
DME as a primary treatment, it may beneﬁt eyes with DME that are
refractory to laser treatment. In a prospective, double-masked,
placebo-controlled, randomized study of 69 eyes with refractory
DME, 55% of treated eyes had visual acuity improvement at 3
months of follow-up compared to only 16% in the placebo group17.
Combination therapy using both laser photocoagulation and IVTA
for DME has been studied, but the results were not consistent
among patients with different severity of diabetic retinopathy.
Patients with non-high risk proliferative diabetic retinopathy (PDR)
and CSME beneﬁted from combination therapy, but those with
NPDR and high risk PDR did not18e21. The therapeutic effect of the
triamcinolone is typically seenwithin 1 week, but in many patients,
re-injections are needed every 3 to 6 months as the effect wears
out. Repeat intravitreal injections may be needed to maintain the
therapeutic effect3,22.
Because of the risk and inconvenience of repeat injections,
intravitreal sustained- release inserts or implants of dexametha-
sone and ﬂuocinolone acetonide for persistent DME were studied
in randomized, controlled trials23e25. The short-term results were
promising and both drugs were well tolerated by patients, but a 3-
year follow-up of intravitreal dexamethasone implants (Retisert)
revealed very high rates of cataracts and glaucoma that required
surgical intervention3.
3.3. Anti-VEGF therapy
VEGF-A is a major mediator of retinal permeability. Blockage of
VEGF can reduce vascular permeability3. There are several drugs
against VEGF that have undergone clinical trials for DME treatment
in recent years, including protein kinase C (PKC) inhibitors, anti-
VEGF aptamers, and anti-VEGF antibodies.
PKC beta-isoform inhibitors: PKC is activated by hyperglycemia;
its b-isoform is an important signaling component for VEGF26.
Selective b-isoform PKC inhibitors can suppress VEGF induced
retinal permeability27. As such, ruboxistaurin (RBX), has been
studied for its effect on DME in a multicenter, double-masked,
randomized, placebo-controlled study of 686 patients. The
authors concluded that daily oral administration of RBX may delay
the progression of DME to a sight-threatening stage28. In another
study of 252 patients with moderate to severe NPDR, 32 mg/day
RBX signiﬁcantly reduced the risk of moderate visual loss compared
to a placebo29. The effect of RBX on long-standing DME has also
been studied; the rate of visual acuity decline was 30% less in
the RBX group compared to the placebo group30. The FDA hasTable 1
The 2-year visual outcome and main complications of DME treatment with laser
photocoagulation or intravitreal injections of triamcinolone studied by Diabetic







Mean BCVA change þ1 2 3
BCVA  10 letters improvement 31% 25% 28%
BCVA  15 letters worse 14% 20% 20%
IOP increased  10 mmHg 4% 16% 33%
Cataract surgery 13% 23% 51%
IVTA¼ intravitreal injection of triamcinolone.requested another phase III trial to determine the efﬁcacy of
moderate and severe NPDR before RBX can be approved.
Anti-VEGF aptamers: Macugen (pegaptanib) is an aptamer that
binds the 165-isoform of VEGF. The efﬁcacy and safety of intra-
vitreal pegaptanib for use in DME treatment were evaluated in
a phase II, randomized, double-masked study of 172 patients31.
Laser photocoagulation and reinjection of pegaptanib were used as
supplemental treatments after the ﬁrst 3 monthly injections. The
results revealed that median visual acuity after 6 months was
signiﬁcantly better in the group with the 0.3 mg intravitreal
injections versus the control group (20/50 vs. 20/63). The propor-
tion of patients with visual acuity improving 10 letters or more was
larger in the 0.3 mg injection group than in the control group (34%
vs. 10%). A solely retrospective study revealed that intravitreal
pegaptanib treatment alone may be superior to macular laser
photocoagulation for DME; further prospective clinical trials are
needed32.
Anti-VEGF antibodies: Ranibizumab and bevacizumab are anti-
VEGF antibodies which have been widely used to treat choroidal
neovascular membranes in age-related macular degeneration.
Because of the important role of VEGF in the blood-retina barrier
breakdown associated with DME, these anti-VEGF antibodies were
studied for the treatment of DME.
Ranibizumab (Lucentis) is a Fab fragment of an anti-VEGF anti-
body. Its efﬁcacy, compared to laser photocoagulation, was studied
in 126 patients with DME in a prospective, randomized, phase II
READ-2 (Ranibizumab for Edema of the mAcula in Diabetes)
study33. The 6-month result of this clinical trial revealed that the
mean gain in BCVA was signiﬁcantly greater in the ranibizumab
injection group compared with the laser photocoagulation group
(þ7.24 vs. e0.43 letters). The rate of BCVA improvement of 3 lines
or more was signiﬁcantly higher in the ranibizumab injection
group. After the primary end point (month 6), most patients in the
READ-2 study were treated only with intravitreal injections of
ranibizumab34. At the end of this 24-month study, the authors
concluded that intraocular injections of ranibizumab provided
beneﬁts for patients with DME, and when combined with focal or
grid laser treatments, the frequency of injections needed to control
edema were reduced.
The RESOLVE study was a 12-month, multicenter, placebo-
controlled, double-masked study with eyes randomly assigned to
receive either intravitreal ranibizumab (0.3 or 0.5 mg) or placebo35.
The treatment schedule comprised 3 monthly injections, after
which treatment could be stopped or reinitiated based on treat-
ment success, disease activity, or safety criteria. Laser photocoag-
ulation could be used as rescue therapy. At month 12, the mean
BCVA improvement from baseline was signiﬁcantly better in the
ranibizumab treated group (combination of 0.3 and 0.5 mg groups)
than the placebo group (þ10.3 vs. e1.4 letters). A gain in the BCVA
of 10 letters over the baseline occurred in 60.8% of eyes in the
ranibizumab group and 18.4% of eyes in the control group. The
mean numbers of injections administered during 12 months were
10.2 and 8.9 for the ranibizumab and controls, respectively. Severe
ocular adverse events (suspected to be drug-related) in the intra-
vitreal ranibizumab group (102 eyes) included vitreous hemor-
rhage (1 eye), retinal artery occlusion (1 eye), and endophthalmitis
(2 eyes). Ocular adverse events which were suspected to be drug-
related included conjunctival hemorrhage (23 eyes) and eye pain
(18 eyes). Non-ocular adverse events potentially related to systemic
VEGF inhibition included arterial thromboembolic events (3
patients), hypertension (9 patients), and nonocular hemorrhage (2
patients).
The Diabetic Retinopathy Clinical Research Network conducted
a phase III, randomized, multicenter clinical trial of 854 DME eyes,
to evaluate the effects of treatment with intravitreal ranibizumab
Table 3
The 1-year visual outcome and main complications of DME treatment with
bevacizumab or laser in the BOLT study.
IVBa (nv42) Laserb (n¼ 38)
Median number of treatments 9 3
BCVA change þ8 0.5
BCVA  10 letters improvement 31.0% 7.9%
BCVA  15 letters worse 2.4% 26.3%
Transient IOP  30 mmHg 7.1% 0
Cataract surgery 14.3% 5.3%
a IVB¼ Intravitreal injection 1.25 mg bevacizumab.
b Laser¼ Focal or grid laser treatment alone.
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compared to focal/grid laser alone36. The 1 year mean change in the
visual acuity letter score from baseline was signiﬁcantly better
in the ranibizumabþ prompt laser group and the ranibizu-
mabþ deferred laser group (Table 2). In a subset of pseudophakic
eyes, visual acuity improvement in the triamcinoloneþ prompt
laser group appeared comparable to that in the ranibizumab
groups. No apparent adverse systemic events attributable to study
treatment were noted. The authors concluded that intravitreal
ranibizumab combined with prompt or deferred laser treatment is
more effective than prompt laser alone for the treatment of DME
involving the central macula.
Bevacizumab (Avastin) is a complete full-length humanized
antibody that binds to all isoforms of VEGF-A. It has been used off-
label for many ocular disorders including age-related macular
degeneration, PDR, retinal vein occlusions, and DME3. In a retro-
spective, non-randomized 24-month study, diffuse DME eyes
treated with intravitreal bevacizumab, demonstrated a signiﬁcant
improvement in mean BCVA and a reduction of mean central
macular thickness compared to baseline37. There were no signiﬁ-
cant differences in visual outcomes between groups treated with
1.25 mg or 2.5 mg of bevacizumab. A 6-month, randomized,
controlled study also found that doses of 1.25 mg and 2.5 mg
seemed to have a similar treatment efﬁcacy38.
Michaelides et al conducted a prospective, randomized, masked,
clinical trial (BOLT study) to compare the efﬁcacy of intravitreal
injections of bevacizumab with that of macular laser therapy in 80
patients with persistent CSME39. The 1-year report revealed that
the median visual gain was signiﬁcantly better in the bevacizumab
group than in the laser group (Table 3).
The efﬁcacy of combining intravitreal bevacizumab with laser
photocoagulation as the primary treatment for diffuse DME was
evaluated in a randomized three arm clinical trial40. The authors
concluded that a combination of intravitreal bevacizumab and
sequential grid laser treatments could be used as an initial treat-
ment for diffuse DME.
There were four prospective, randomized, clinical trials con-
ducted to compare the efﬁcacy of combination therapy using bev-
acizumab and triamcinolone with monotherapy or macular laser
photocoagulation41e44. Only one of these studies reportedmarginal
improvements in BCVA using combination therapy42. No further
beneﬁcial effects of combination therapy using bevacizumab and
triamcinolone were demonstrated in the other studies.
3.4. Vitrectomy
It has been hypothesized that the role of the vitreous in DME
involves mechanical traction of the vitreoretinal interface and the
accumulation of factors altering vascular permeability (e.g. VEGF)
in the vitreous3. Vitrectomy, with posterior hyaloid removal or
internal limiting membrane (ILM) peeling, can remove these twoTable 2
The 1-year visual outcome and main complications of DME treatment with ranibizumab p
Retinopathy Clinical Research Network.
IVRa (n¼ 188) IVRþ laserb (
Median number of injections 9 8
BCVA change þ9 þ9
BCVA  10 letters improvement 47% 50%
BCVA  15 letters worse 2% 2%
IOP increased  10 mmHg 3% 5%
Cataract surgery 6% 5%
a IVR¼ intravitreal injection 0.5 mg ranibizumab.
b IVRþ laser¼ intravitreal injection 0.5 mg ranibizumab with prompt laser treatment
c IVTAþ laser¼ intravitreal injection 4 mg triamcinolone with prompt laser treatmen
d Shamþ laser¼ sham injection and prompt laser treatment.factors from diabetic eyes. The safety and efﬁcacy of these proce-
dures have been studied and are discussed in the literature.
Otani and Kishi conducted a nonrandomized trial to compare 7
vitrectomized eyes with untreated fellow to assess the efﬁcacy of
vitrectomy for DME45. Among patients undergoing vitrectomy, the
BCVA improved in 57% and remained unchanged in 43% of the
patients. In the control group, visual acuity improved in 14%,
remained unchanged in 43%, and decreased in 43% of eyes. Stolba
et al conducted a prospective, randomized study to compare the
visual outcomes of eyes treated with vitrectomy and ILM peeling
with control eyes46. This study enrolled 56 eyes with persistent
DME. They found that the vitrectomy group had signiﬁcantly better
visual acuity and retinal thickness changes at 1, 3, and 6 months.
The Diabetic Retinopathy Clinical Research Network conducted
a prospective cohort study of 87 eyes, to evaluate vitrectomy for
DME with at least moderate vision loss and vitreomacular trac-
tion47. At 6 months, they reported that 68% of the vitrectomized
eyes had at least a 50% reduction in central retinal thickness. Visual
acuity improved by 10 letters or more in 38% and deteriorated by 10
letters or more in 22% of vitrectomized eyes.
The comparison of vitrectomy and laser photocoagulation on
the treatment of persistent DME has been studied by a pilot
randomized trial of 20 eyes48. Patel et al reported that there was
little evidence of any difference in foveal thickness between the
two treatments at 12 months, but that the laser group showed
a slight but signiﬁcant improvement in ETDRS vision compared to
the vitrectomy group. The role of ILM peeling in DME treatment has
been evaluated in a prospective, randomized study. Bahadir et al
reported that the visual acuity outcomes in eyes with vitrectomy
without ILM peeling were just as effective as those in the eyes with
both vitrectomy and ILM peeling49.
The reported complications of vitrectomy for DME include
cataracts (7.5e10%), choroidal detachment (8%), epiretinal
membrane (8e10.3%), ﬁbrinoid syndrome (8%), glaucoma (1.7e8%),
development of hard exudates (3%), macular ischemia (10%),
neovascular glaucoma (3.4e8%), retinal detachment (10%), retinal
tear (10e20.7%), tractional rhegmatogenous retinal detachment
(1.7%), and vitreous hemorrhage (12.1e16%)3.lus prompt or deferred laser or triamcinolone plus prompt laser studied by Diabetic









Current Treatments of Diabetic Macular Edema 1873.5. Subthreshold micropulse diode laser photocoagulation
(SMDLP)
The mechanism of action of SMDLP is based on the delivery of
laser pulses that are shorter in duration than the thermal relaxation
time of RPE cells. A micropulse laser produces slight temperature
increases, selectively damaging RPE cells but not the adjacent
photoreceptors or choriocapillaries. SMDLP may have the potential
to eliminate the side effects of paracentral scotoma and scar
formation3.
The efﬁcacy and safety of SMDLP in treating DME, compared to
conventional lasers, were studied in three prospective, randomized
clinical trials50e52. The results indicated that the visual outcomes of
both types of lasers were equal. Scar formation was less in the
SMDLP group, and the central retinal sensitivity was signiﬁcantly
increased in the SMDLP group52.4. Conclusion
DME is the major cause of visual impairment in diabetic
patients. Macular laser photocoagulation has been the standard
treatment for DME during the past 2 decades. Although it can
reduce the risk of moderate visual loss in CSME, only a few patients
can experience visual improvement after treatment. Macular laser
photocoagulation is not beneﬁcial in patients with diffuse DME.
Several prospective clinical trials for new modalities of DME
treatments were completed in the past few years. The anti-VEGF
antibody, ranibizumab, has shown a greater potential than laser
treatment in improving visual outcomes of patients with DME in
the phase III trial. The bevacizumab, although it was off-label used,
demonstrated similar efﬁcacy in smaller prospective trials.
Prospective trials for the comparison of the efﬁcacy and compli-
cations of treating DME with these 2 VEGF antibodies may be
needed. Patients have to receive multiple injections of the VEGF
antibodies to maintain the visual gain. The cost implications and
risk associated with of injection-related complications increase
with the number of injections.
Several trails involving different combinations of treatment
modalities for DME have been conducted, including laser therapy,
and intravitreal injection of triamcinolone acetonide, bevacizumab,
or ranibizumab. However, these combination therapies have not
proved more efﬁcacious than monotherapy with anti-VEGF anti-
bodies. Since the pathogenesis of DME involves multiple factors,
further investigation of a combination of laser, pharmacological
and surgical treatment modalities may be needed to achieve the
best outcome of DME treatment.References
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